Is mirabegron (beta-3 adrenergic agonist) a suitable treatment option for primary nocturnal enuresis in a 27-year-old woman?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 18, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Mirabegron is Not Indicated for Primary Nocturnal Enuresis

Mirabegron should not be used for primary nocturnal enuresis in a 27-year-old woman, as it is specifically indicated only for overactive bladder syndrome, not for enuresis. The established treatments for adult primary nocturnal enuresis are desmopressin, enuresis alarms, and imipramine 1.

Why Mirabegron is Inappropriate

  • Mirabegron is a β3-adrenoceptor agonist approved exclusively for overactive bladder symptoms (urgency, frequency, urge incontinence), not for nocturnal enuresis 2, 3.

  • The mechanism of action—bladder relaxation during filling and increased bladder capacity—addresses daytime storage symptoms rather than the pathophysiology of primary nocturnal enuresis, which involves nocturnal polyuria, arousal dysfunction, and/or nocturnal detrusor overactivity 2, 4.

  • No guidelines or research evidence supports mirabegron use for primary nocturnal enuresis 5, 2.

Appropriate Treatment Approach for Adult Primary Nocturnal Enuresis

First-Line Therapy: Desmopressin

  • Desmopressin 20-40 mcg nightly is the initial pharmacotherapy of choice, achieving continence in 66% of adult patients with primary nocturnal enuresis 1.

  • However, only 7% maintain continence after discontinuation, indicating most patients require ongoing therapy 1.

Second-Line Therapy: Enuresis Alarm

  • For patients who fail desmopressin or relapse after discontinuation, an enuresis alarm for 6 months should be initiated 1.

  • Enuresis alarms achieved continence in 33% of patients who were non-responsive to desmopressin, with better long-term cure rates off medication 1.

Third-Line Therapy: Imipramine

  • Imipramine 50 mg nightly can be considered for patients unresponsive to both desmopressin and enuresis alarms 1.

  • In refractory cases, imipramine achieved continence in 29% of patients who failed other modalities 1.

Overall Treatment Success

  • Using this sequential approach, 83% of adult patients with primary nocturnal enuresis achieve continence: 38% remain dry off all medications and 45% maintain continence on ongoing pharmacotherapy 1.

Critical Distinction: Enuresis vs. Nocturia

  • Primary nocturnal enuresis (involuntary urination during sleep without waking) differs fundamentally from nocturia (waking to void intentionally) 5.

  • The evaluation for persistent nocturia in adults should screen for underlying SCREeN conditions (Sleep disorders, Cardiovascular disease, Renal disease, Endocrine disorders, Neurological conditions) 5.

  • If this patient actually has nocturia rather than true enuresis, a 72-hour bladder diary, assessment for nocturnal polyuria, and screening for medical comorbidities would be appropriate before considering any pharmacotherapy 5.

References

Guideline

Mirabegron 25mg for Overactive Bladder Treatment

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

[MIRABEGRON--A NEW DRUG FOR TREATMENT OF OVERACTIVE BLADDER].

Urologiia (Moscow, Russia : 1999), 2015

Research

Use of mirabegron in treating overactive bladder.

International urogynecology journal, 2012

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.